SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

Advanced Micro Devices is surging as investors cheer a quarterly financial beat driven by explosive data center demand and optimism around the company's AI accelerator growth. The market is buzzing with excitement over raised price targets and the potential for long-term expansion, leading to intense community discussion regarding the sustainability of this rally and its role in the broader semiconductor sector.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is currently facing intense community frustration as it trades sideways while competitors like AMD see significant parabolic moves. Investors remain divided between concerns over valuation saturation and anticipation for an upcoming earnings beat that could finally trigger a major breakout.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

The S&P 500 is surging on renewed market optimism fueled by reports of potential diplomatic breakthroughs in the Iran conflict and sustained strength in the AI-driven tech sector. While traders are actively debating the sustainability of this rally and expressing frustration over market volatility, institutional sentiment remains robust as investors continue to rotate into equities despite concerns regarding global energy supplies and ongoing geopolitical tensions.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is trending as traders navigate extreme bullish momentum driven by AI-focused semiconductor strength and ongoing geopolitical speculation regarding potential peace deals in the Middle East. While retail investors continue to pile into tech assets, the community remains sharply divided between those betting on an endless parabolic rally and others cautioning that technical indicators suggest the market is significantly overextended.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is seeing intense social media chatter as shareholders rally behind activist investor Himanshu Shahs call to vote against executive compensation and board re-elections due to persistent stock underperformance. Investors are aggressively speculating that pending partnership deals, particularly regarding Pfizers use of Matrix-M in pneumococcal vaccine development, could serve as the major catalyst needed to finally break the stock out of its long-term trading range.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

Semiconductor bears are feeling the intense pressure of a relentless, momentum-driven bull market that continues to ignore geopolitical risks and valuation concerns, leaving investors torn between capitulation and holding out for a long-awaited reversal. The community is actively debating the sustainability of the current melt-up, with many traders frustrated by consistent after-hours rallies and a persistent disconnect between sector earnings and price action.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is currently trending as investors speculate on upcoming international expansion and potential FDA updates, fueling heavy discussion around a possible short squeeze given the elevated short interest. Community sentiment remains aggressively bullish, with many focusing on the company's progress with Anktiva and Dr. Patrick Soon-Shiong's recent, cryptic social media activity signaling global momentum.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with mobility drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, and taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting carriers with shippers on its platform, and gives carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Uber is trending as the market evaluates its aggressive pivot toward autonomous vehicle infrastructure and a deepened partnership with Lucid, which investors are analyzing as a long-term catalyst for growth. While the community remains divided over short-term price action and competitive headwinds, many are focused on the potential for margin expansion as Uber positions itself as the primary operating system for the autonomous era.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is trending as investors digest Michael Saylors pivot toward potentially selling Bitcoin to fund dividends, while the community intensely debates whether this strategy signals a sustainable evolution into a crypto-leveraged financial vehicle or a long-term dilution risk. Despite mixed reactions to earnings, market sentiment remains heavily tied to Bitcoin's price action as bulls watch for a breakout above psychological resistance levels.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending as investors react to strong weekly prescription data for its Wegovy pill, which is outperforming competitor launches and helping revive sentiment around the company's growth outlook. Community discussion is focused on the potential for a share price recovery leading into upcoming earnings, as many investors argue the stock is deeply undervalued relative to its dominant market position in the GLP-1 sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$IBRX $IOVA The complex scalability, cost and nominal efficacy make IOVA a pale choice against IBRX

cyberInvest

Lindzcav

Justlosing

Charles ford

FL Man

StockTwits for iOS

Iovance Biotherapeutics Inc

Karly Herman

$IOVA $IBRX the not dying of cancer makes IBRX a pale choice against IOVA.

barbaresqo

$IBRX $IOVA here is one with bait and switch

 The complex scalability, cost and nominal efficacy make IOVA a pale choice against IBRX

Pork fried rice

@Adi121 they’re desperate. I don’t believe anyone posts there from here.

Chad Schott

 they’re desperate. I don’t believe anyone posts there from here.

StockTwits Web

Jeff Poburka

@Adi121 IBRX financials are much worse and in biotech, cash runway is king.  Until you have a path to profitability, biotech is only a trade.

Fire_Truck

Kevin Roger

Scooot

Raylin Jones

 IBRX financials are much worse and in biotech, cash runway is king.  Until you have a path to profitability, biotech is only a trade.

George Hansen

@GMH21 research IBRX owner and its rate of revenue growth, you will get some enlightenment! I have no beef against you guys, don’t come on IBRX board to post trash. IBRX is a global play for longevity, cancer and other incurable viral diseases  that makes every human a potential recepient!

 research IBRX owner and its rate of revenue growth, you will get some enlightenment! I have no beef against you guys, don’t come on IBRX board to post trash. IBRX is a global play for longevity, cancer and other incurable viral diseases  that makes every human a potential recepient!

@Adi121 Read the financials... dilution is the death knell of biotech.  Yes, founder owns 80% of the shares... and that is part of the problem.  Low float so the SP gets pumped, but then they need to raise cash and SP gets cut in half.  They have always run on 1-2 quarters of cash.  Operating cashflow consistently negative $70-80M and current cash $90M.  If I were to play IBRX, I would buy the next dilution and flip in &lt;90 days.

Bilar

 Read the financials... dilution is the death knell of biotech.  Yes, founder owns 80% of the shares... and that is part of the problem.  Low float so the SP gets pumped, but then they need to raise cash and SP gets cut in half.  They have always run on 1-2 quarters of cash.  Operating cashflow consistently negative $70-80M and current cash $90M.  If I were to play IBRX, I would buy the next dilution and flip in <90 days.

@GMH21 ok let me tell you one thing ,  IOVA sales peak this year. You can bookmark it and come back next year!

 ok let me tell you one thing ,  IOVA sales peak this year. You can bookmark it and come back next year!

@Adi121 If that is your thesis, then fine. Don&#39;t invest in IOVA.  I do not care, I never asked you too and if you do or do not, it will not make one bit of difference to the share price.

Bi Low Sell Higher

 If that is your thesis, then fine. Don't invest in IOVA.  I do not care, I never asked you too and if you do or do not, it will not make one bit of difference to the share price.

@Adi121 I understand the other guy started it but cross posting is a fool’s errand. Doubly so when it’s done without respect or due diligence.

Real AF biznas

 I understand the other guy started it but cross posting is a fool’s errand. Doubly so when it’s done without respect or due diligence.